Semaglutide (Wegovy)

Peptide

Also known as NN9536

Approvedregulatory verdict

Evidence outlook

Approved: Obesity, Atherosclerotic Cardiovascular Disease, MASH / NASH [accelerated] (label: adults; noncirrhotic, moderate to advanced fibrosis)

Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Heart Failure with Preserved Ejection Fraction · Phase 3 · investigational in the US

Also approved (3)
JP
  • Wegovy: obesity disease (restricted to BMI >=27 with two or more obesity-related disorders, or BMI >=35)
Product first approved 2023pj.jiho.jp
EU
  • Wegovy: weight management (weight loss and maintenance) in adults with BMI >=30, or >=27 with a weight-related comorbidity
Product first approved 2022EMA
CA
  • WEGOVY® (semaglutide injection) is indicated: • as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: o Adult patients with an initial body mass index (BMI) of ▪ 30 kg/m2 or greater (obesity), or ▪ 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea. o Pediatric patients aged 12 to less than 18 years: ▪ with an initial BMI at the 95th percentile or greater for age and sex (obesity; see Table 1), and ▪ a body...
Product first approved 2021Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (37)
Heart Failure with Preserved Ejection Fraction
NCT04916470 · Novo Nordisk A/S
2021-06-15 – 2023-10-11 · Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
What this study did
MASH / NASH
Obesity
NCT06934655 · Children's Hospital Los Angeles
2026-09-01 – 2033-11-01 · Pediatric Obesity, Metabolic and Bariatric Surgery, Semaglutide
What this study did
NCT07253285 · Novo Nordisk A/S
2026-01-08 – 2033-09-20 · Overweight, Obesity
What this study did
NCT07949474 · University of Minnesota
2027-05-01 – 2033-04-30 · Alcohol Use Disorder (AUD), Obesity
What this study did
NCT07021937 · University of Colorado, Denver
2026-06-15 – 2031-04-30 · Obesity/Therapy
What this study did
NCT07294950 · Mount Sinai Hospital, Canada
2026-02-01 – 2029-05 · Obesity (Disorder), Weight Change, Blood Pressure Monitoring, Appetite Regulation
What this study did
NCT06909006 · Nordsjaellands Hospital
2025-10 – 2028-06 · Obesity in Diabetes, Obesity/Therapy, Type 1 Diabetes Mellitus (T1DM), Insulin Sensitivity/Resistance, Semaglutide, Lipidomics, Metabolomics, Weight Loss, Glycemic Control for Diabetes Mellitus
What this study did
NCT06499857 · University of Chicago
2025-04-14 – 2028-06 · Overweight or Obesity, Atrial Fibrillation
What this study did
NCT06937060 · The University of Hong Kong
2025-03-20 – 2027-01-31 · Psoriasis (PsO), Obesity and Overweight
What this study did
NCT05726227 · Novo Nordisk A/S
2023-07-07 – 2026-12-07 · Obesity
What this study did
NCT06633783 · Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
2024-10-30 – 2026-10-30 · Obesity
What this study did
NCT06616961 · Popular Medical College Hospital
2024-11-01 – 2026-10 · Obesity, Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06041217 · Novo Nordisk A/S
2023-09-15 – 2025-05-07 · Overweight, Obesity
What this study did
NCT05073835 · University College, London
2022-11-01 – 2025-04-09 · Obesity, Diabetes, Metabolic Syndrome
What this study did
NCT05813925 · Novo Nordisk A/S
2023-04-03 – 2025-03-07 · Obesity or Overweight
What this study did
NCT05996848 · Novo Nordisk A/S
2023-08-15 – 2025-02-22 · Obesity or Overweight
What this study did
NCT05646706 · Novo Nordisk A/S
2023-01-04 – 2024-11-26 · Obesity
What this study did
NCT04885634 · Axel Brandes
2022-10 – 2024-11 · Atrial Fibrillation, Overweight and Obesity
What this study did
NCT05087342 · Loma Linda University
2022-12-13 – 2024-05-29 · Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss, Weight Loss Trajectory, Weight, Body
What this study did
NCT04889183 · University Medical Center Groningen
2022-03-14 – 2024-05-28 · Obesity, Albuminuria
What this study did
NCT04998136 · Novo Nordisk A/S
2022-08-15 – 2023-11-20 · Obesity
What this study did
NCT05064735 · Novo Nordisk A/S
2021-10-01 – 2023-09-08 · Obesity
What this study did
NCT05040971 · Novo Nordisk A/S
2021-09-06 – 2023-07-14 · Obesity
What this study did
NCT04788511 · Novo Nordisk A/S
2021-03-16 – 2023-04-18 · Obesity
What this study did
NCT04251156 · Novo Nordisk A/S
2020-12-08 – 2022-08-23 · Overweight, Obesity, Diabetes Mellitus, Type 2
What this study did
NCT04102189 · Novo Nordisk A/S
2019-10-07 – 2022-03-28 · Overweight, Obesity
What this study did
NCT04074161 · Novo Nordisk A/S
2019-09-11 – 2021-05-11 · Overweight, Obesity
What this study did
NCT03693430 · Novo Nordisk A/S
2018-10-05 – 2021-03-23 · Overweight, Obesity
What this study did
NCT03811574 · Novo Nordisk A/S
2019-01-21 – 2020-11-20 · Overweight, Obesity
What this study did
Other / comorbidity
NCT07090343 · Leiden University Medical Center
2026-04-01 – 2031-04-01 · Aortic Stenosis, Heart Failure
What this study did
Phase 2/3 (4)
Obesity
NCT06423599 · Jens D Hove, MD,PHD
2024-04-30 – 2027-12-30 · Heart Failure With Reduced Ejection Fraction, Obesity, Weight Loss, Chronic Heart Failure
What this study did
NCT06896981 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2025-01-01 – 2026-02-28 · Polycystic Ovary Syndrome (PCOS) Women, Obesity
What this study did
Other / comorbidity
NCT07797036 · University of Massachusetts, Worcester
2027-09-01 – 2030-12-31 · Gestational Diabetes Mellitus (GDM), Metabolic Syndrome
What this study did
NCT06913023 · University Health Network, Toronto
2026-12-05 – 2029-12-30 · Kidney Transplant Recipient
What this study did
Phase 2 (30)
MASH / NASH
NCT03884075 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2019-07-24 – 2028-10-02 · Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
What this study did
NCT04971785 · Gilead Sciences
2021-08-09 – 2024-12-09 · Nonalcoholic Steatohepatitis
What this study did
NCT03987451 · Novo Nordisk A/S
2019-06-18 – 2021-06-10 · Non-alcoholic Steatohepatitis
What this study did
NCT03987074 · Gilead Sciences
2019-07-29 – 2020-07-13 · Nonalcoholic Steatohepatitis
What this study did
NCT02970942 · Novo Nordisk A/S
2016-11-30 – 2020-03-19 · Hepatobiliary Disorders, Non-alcoholic Steatohepatitis
What this study did
Obesity
NCT05829460 · Washington University School of Medicine
2025-03-12 – 2032-04-30 · Endometrial Hyperplasia
What this study did
NCT07820358 · The Methodist Hospital Research Institute
2027-01-01 – 2031-12-31 · Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer, Fertility-Sparing Treatment (FST), Obesity & Overweight
What this study did
NCT07731256 · Washington University School of Medicine
2027-02-01 – 2031-09-01 · Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
What this study did
NCT07946796 · Copenhagen University Hospital at Herlev
2027-01 – 2029-10 · Infertility in Overweight Men
What this study did
NCT07909889 · Aarhus University Hospital
2027-03 – 2029-09 · Breast Cancer (Early Breast Cancer), Obesity
What this study did
NCT06173778 · The University of Texas Health Science Center, Houston
2024-04-23 – 2028-06-25 · Obesity, Overweight, Cigarette Smoking
What this study did
NCT07411378 · Biophytis
2026-07 – 2027-08 · Muscle Wasting, Obesity & Overweight, Obesity
What this study did
NCT07639021 · Novo Nordisk A/S
2026-06-09 – 2027-06-14 · Obesity
What this study did
NCT05173714 · Srinvasan Beddhu
2021-12-01 – 2027-03-31 · Chronic Kidney Diseases, Obesity
What this study did
NCT07101939 · Actimed Therapeutics Ltd
2025-06-23 – 2027-03 · Obesity, Muscle Loss
What this study did
NCT05254314 · Vanderbilt University Medical Center
2022-10-11 – 2026-12-30 · Asthma
What this study did
NCT07505303 · Eccogene
2026-03-23 – 2026-10-15 · Adult Obesity, Weight Management
What this study did
NCT04019197 · Case Western Reserve University
2019-05-16 – 2026-10-09 · HIV/AIDS, Lipohypertrophy, Obesity
What this study did
NCT04873245 · University of Minnesota
2022-03-15 – 2026-06-30 · Obesity, Childhood
What this study did
NCT06771115 · Zomagen Biosciences Ltd.
2025-01-07 – 2025-09-10 · Obesity
What this study did
NCT05895643 · Psychiatric Centre Rigshospitalet
2023-06-13 – 2025-07-31 · Alcohol Abuse, Alcohol Addiction, Alcohol Dependence, Alcohol Use Disorder
What this study did
NCT05616013 · Eli Lilly and Company
2022-11-16 – 2025-06-14 · Obesity, Obese, Overweight or Obesity
What this study did
NCT05302596 · State University of New York at Buffalo
2022-09-01 – 2024-10-30 · Obesity, Aging
What this study did
NCT04969939 · Novo Nordisk A/S
2021-07-15 – 2023-01-30 · Obesity
What this study did
NCT02453711 · Novo Nordisk A/S
2015-10-01 – 2017-04-12 · Metabolism and Nutrition Disorder, Obesity
What this study did
Other / comorbidity
NCT06073184 · GynOncTrials
2026-09-17 – 2032-02 · Endometrial Cancer, Atypical Hyperplasia, Fertility Perservation
What this study did
NCT07282769 · University of Chicago
2026-06 – 2027-02 · Trichotillomania (Hair-Pulling Disorder), Trichotillomania, Hair Pulling Disorder, Hair Pulling, Hair-Pulling Disorder
What this study did
NCT04982575 · Novo Nordisk A/S
2021-08-02 – 2022-07-07 · Diabetes Mellitus, Type 2
What this study did
Phase 1/2 (2)
Obesity
NCT05746039 · University of Pennsylvania
2024-01-29 – 2027-12-28 · Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
What this study did
NCT06541509 · University Medical Centre Ljubljana
2024-07-10 – 2025-09-01 · Heart Failure, Obesity
What this study did
Phase 1 (24)
MASH / NASH
NCT05766709 · Novo Nordisk A/S
2023-03-02 – 2024-02-09 · Non-alcoholic Steatohepatitis
What this study did
Obesity
NCT07527195 · Novo Nordisk A/S
2026-04-10 – 2028-06-09 · Obesity
What this study did
NCT07010432 · Novo Nordisk A/S
2025-06-12 – 2028-05-03 · Obesity
What this study did
NCT06575738 · University of Colorado, Denver
2024-10-11 – 2027-10-01 · Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents
What this study did
NCT07845578 · Novo Nordisk A/S
2026-09-25 – 2027-09-11 · Obesity, Overweight
What this study did
NCT07840729 · Shanghai JMT-Bio Inc.
2026-10-20 – 2027-04-30 · Valid MeSH Conditiongs
What this study did
NCT05202353 · Boehringer Ingelheim
2024-11-01 – 2027-02-03 · Obesity
What this study did
NCT07465965 · Shanghai World Leader Pharmaceutical Co., Ltd.
2026-03-02 – 2026-08-30 · Overweight, Obesity
What this study did
NCT07171723 · University Hospital, Gentofte, Copenhagen
2025-09-01 – 2026-08-12 · Obesity &Amp; Overweight
What this study did
NCT06972992 · Ascletis Pharma (China) Co., Limited
2025-04-18 – 2025-09-22 · Chronic Weight Management
What this study did
NCT04779697 · Yale University
2021-02-01 – 2024-11-19 · Obesity
What this study did
NCT05236517 · Novo Nordisk A/S
2022-02-08 – 2022-11-07 · Obesity
What this study did
NCT04238962 · Novo Nordisk A/S
2020-02-03 – 2020-10-20 · Overweight, Obesity
What this study did
NCT04187300 · Novo Nordisk A/S
2019-12-16 – 2020-09-23 · Overweight, Obesity
What this study did
NCT03600480 · Novo Nordisk A/S
2018-07-25 – 2020-06-12 · Obesity, Overweight
What this study did
NCT04228354 · Novo Nordisk A/S
2020-01-29 – 2020-06-01 · Healthy Volunteers, Overweight, Obesity
What this study did
NCT03842202 · Novo Nordisk A/S
2019-02-15 – 2019-11-04 · Overweight, Obesity
What this study did
NCT04012255 · Novo Nordisk A/S
2019-07-15 – 2019-10-22 · Overweight, Obesity
What this study did
NCT03707990 · Novo Nordisk A/S
2018-10-15 – 2019-08-13 · Obesity and Overweight
What this study did
NCT03574584 · Novo Nordisk A/S
2018-06-18 – 2019-07-27 · Metabolism and Nutrition Disorders, Overweight or Obesity
What this study did
Other / comorbidity
NCT07727473 · Banner Health
2026-07 – 2029-05 · Prostate Cancer
What this study did
Phase 4 (40)
Heart Failure with Preserved Ejection Fraction
NCT05371496 · Mayo Clinic
2022-09-06 – 2026-07-17 · Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
What this study did
MASH / NASH
Semaglutide vs Sitagliptinactive not recruiting
NCT05195944 · University Health Network, Toronto
2022-10-26 – 2026-12 · Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD
What this study did
Obesity
NCT07769047 · Mayo Clinic
2026-09-01 – 2035-07-30 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
What this study did
NCT06977438 · University of Minnesota
2027-01-01 – 2032-01-31 · Obesity, Childhood
What this study did
NCT06571383 · Novo Nordisk A/S
2024-09-17 – 2031-11-15 · Obesity
What this study did
NCT07872904 · Signe Torekov
2026-10-01 – 2031-01-31 · Obesity, Overweight
What this study did
NCT07592546 · Alain Dagher
2026-10-21 – 2030-06-01 · Class I/II Obesity
What this study did
NCT07900074 · McMaster University
2026-10-31 – 2029-12-31 · Obesity (Disorder)
What this study did
NCT07770152 · Children's Hospital Medical Center, Cincinnati
2026-10-18 – 2029-09-01 · Autism Spectrum Disorder, Obesity
What this study did
NCT07783854 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-09-01 – 2029-06-30 · Obesity & Overweight
What this study did
NCT07859150 · General Committee of Teaching Hospitals and Institutes, Egypt
2026-10 – 2029-04 · Morbid Obesity
What this study did
NCT07859163 · General Committee of Teaching Hospitals and Institutes, Egypt
2026-10 – 2029-04 · Morbid Obesity
What this study did
NCT07213466 · Mayo Clinic
2026-01-19 – 2029-02-01 · Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
What this study did
NCT07858331 · Kristin Clemens
2027-01-01 – 2029-01-01 · Obesity, Chronic Kidney Disease, Chronic Renal Disease, CKD
What this study did
NCT07275697 · Emma Svennberg
2026-03-23 – 2028-12-30 · Atrial Fibrillation (AF), Obesity & Overweight
What this study did
NCT07870538 · Universitaire Ziekenhuizen KU Leuven
2026-08-26 – 2028-12 · Obesity & Overweight
What this study did
NCT06814938 · Mayo Clinic
2025-02-21 – 2028-11 · Obesity
What this study did
NCT07859137 · General Committee of Teaching Hospitals and Institutes, Egypt
2026-10 – 2028-11 · Morbid Obesity
What this study did
NCT07859189 · General Committee of Teaching Hospitals and Institutes, Egypt
2026-10 – 2028-10 · Morbid Obesity
What this study did
NCT05209165 · San Francisco Veterans Affairs Medical Center
2023-05 – 2028-05 · Atrial Fibrillation, Obesity, Overweight
What this study did
NCT06854614 · The Cleveland Clinic
2025-03-01 – 2028-04-28 · Obesity
What this study did
NCT07859176 · General Committee of Teaching Hospitals and Institutes, Egypt
2026-10 – 2028-04 · Morbid Obesity
What this study did
NCT06852391 · McMaster University
2025-06-18 – 2027-12-31 · Obesity (Disorder)
What this study did
NCT06754163 · St Andrew's Healthcare
2025-01-01 – 2027-12-30 · Obesity and Obesity-related Medical Conditions, Psychiatric Disorders
What this study did
NCT06803888 · Ali Aminian
2025-01-29 – 2027-12-01 · Obesity and Obesity-related Medical Conditions
What this study did
NCT07136714 · Nordsjaellands Hospital
2025-09-11 – 2027-09 · Major Depressive Disorder
What this study did
NCT07242534 · Fundacion Dexeus
2026-01-19 – 2027-05 · Infertility, Obesity
What this study did
NCT07057310 · Mayo Clinic
2025-05-01 – 2027-03-31 · Obesity, Menopause
What this study did
NCT06396416 · Western University, Canada
2024-09-26 – 2026-12 · Obesity, Chronic Kidney Disease
What this study did
NCT06287307 · Zuyderland Medisch Centrum
2024-05 – 2026-09 · Obesity, Obesity, Morbid, Weight Gain
What this study did
NCT05574439 · Signe Torekov
2022-05-30 – 2026-04-01 · Obesity, Adolescent
What this study did
NCT06027567 · Rigmor Højland Jensen
2022-09-02 – 2025-10-28 · Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity, Pseudotumor Cerebri Syndrome, Papilledema, Weight Loss
What this study did
NCT05702905 · Peking University First Hospital
2023-05-09 – 2025-06-30 · PCOS (Polycystic Ovary Syndrome), Semaglutide
What this study did
NCT05548647 · University of Pennsylvania
2022-07-26 – 2025-05-12 · Obesity
What this study did
NCT06468748 · United States Army Research Institute of Environmental Medicine
2024-08-01 – 2025-03-27 · Obesity
What this study did
NCT06863363 · Shanghai Zhongshan Hospital
— · Non-diabetic Obesity
What this study did
NCT05579249 · Novo Nordisk A/S
2023-01-19 – 2024-11-27 · Obesity
What this study did
NCT04263415 · University Medical Centre Ljubljana
2019-11-02 – 2021-10-31 · PCOS, Semaglutide, Taste, Altered, Tongue Tissue Transcriptome, Gastric Emptying, Central Neural Response
What this study did
Other / comorbidity
NCT05616052 · Huashan Hospital
2022-12-01 – 2023-12-01 · Weight Change, Body
What this study did
Early phase / not applicable (21)
MASH / NASH
NCT06764056 · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
2025-01 – 2026-05 · Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH), Obesity
What this study did
Obesity
NCT07621640 · Hallym University
2026-06 – 2031-02 · Obesity, Metabolic Syndrome, Brown Adipose Tissue
What this study did
NCT06885736 · Dasman Diabetes Institute
2025-08-07 – 2029-12-31 · Obesity
What this study did
NCT07589322 · Tri-Service General Hospital (TSGH)
2026-03-31 – 2029-09-30 · Obesity and Metabolic Syndrome
What this study did
NCT07732426 · Seoul National University Hospital
2026-07-15 – 2028-06-30 · Food Addiction Tendency, Obesity, Overweight
What this study did
NCT07633639 · China-Japan Friendship Hospital
2026-05-01 – 2028-05-01 · Obesity
What this study did
NCT07779343 · University of Health Sciences, Algeria
2026-01-22 – 2028-01-23 · Obesity Difficult Airway Airway Management, Obesity Adult Onset, Obesity and Cardiovascular Risk, Obesity Type 2 Diabetes Mellitus
What this study did
NCT06825793 · Beijing Chao Yang Hospital
2025-02-20 – 2027-12-31 · Obesity
What this study did
NCT06497595 · Sheba Medical Center
2025-05-11 – 2027-11-30 · Type 2 Diabetes Mellitus in Obese
What this study did
NCT04174755 · University College Dublin
2022-06-22 – 2027-07 · Obesity, HIV-1-infection
What this study did
NCT07293325 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-06-02 – 2027-06-02 · Adults With Simple Obesity
What this study did
NCT06546384 · Insel Gruppe AG, University Hospital Bern
2026-11-01 – 2027-04-30 · Adiposity, Fatty Liver, Alcohol Use Disorder
What this study did
NCT06989203 · Chinese Academy of Sciences
2025-06-10 – 2026-12-31 · Obesity, Weight Loss, Protein Supplementation
What this study did
NCT07319975 · Istanbul Galata University
2025-12-29 – 2026-12 · Obesity
What this study did
NCT05333003 · Centre for Addiction and Mental Health
2022-05-25 – 2026-08 · Schizophrenia Spectrum Disorders
What this study did
NCT04990024 · American University of Beirut Medical Center
2021-07-01 – 2025-12-15 · Obesity, Weight Loss
What this study did
NCT07280403 · INQUIS Clinical Research
2024-09-12 – 2025-11-30 · Weight Loss
What this study did
NCT06390501 · Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
2024-04-01 – 2025-09-15 · Obesity; Drug
What this study did
NCT06426446 · Assistance Publique - Hôpitaux de Paris
2024-06-01 – 2025-06-01 · Obesity
What this study did
NCT06221696 · S.LAB (SOLOWAYS)
2023-06-12 – 2023-12-01 · Overweight and Obesity
What this study did
NCT06215196 · S.LAB (SOLOWAYS)
2023-04-14 – 2023-08-20 · Overweight and Obesity
What this study did
Used as active comparator (29)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (14)
Obesity
NCT07668414 · Novo Nordisk A/S
2026-09-22 – 2028-10-10 · Overweight, Obesity
What this study did
NCT07919405 · Novo Nordisk A/S
2026-11-11 – 2028-07-13 · Hypertension, Obesity
What this study did
NCT07564414 · Novo Nordisk A/S
2026-05-21 – 2028-04-19 · Obesity, Type 2 Diabetes
What this study did
NCT07845500 · Pfizer
2026-09-30 – 2028-02-16 · Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
What this study did
NCT07622810 · Carnot Laboratories
2026-09 – 2027-12 · Obesity & Overweight
What this study did
NCT07150975 · Gan & Lee Pharmaceuticals.
2025-09-23 – 2027-06-30 · Obesity/Overweight in Adult
What this study did
NCT06884293 · Innovent Biologics (Suzhou) Co. Ltd.
2025-05-09 – 2027-06-30 · Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
What this study did
NCT07285902 · Fujian Shengdi Pharmaceutical Co., Ltd.
2025-12-25 – 2027-03 · Obesity
What this study did
NCT05567796 · Novo Nordisk A/S
2022-11-01 – 2026-10-19 · Obesity
What this study did
NCT06738979 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2025-03-20 – 2026-05-26 · Obesity
What this study did
NCT07036172 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2025-01-03 – 2026-05 · Obesity Control
What this study did
NCT06604624 · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
2024-09-20 – 2025-09-24 · Weight Management
What this study did
NCT05822830 · Eli Lilly and Company
2023-04-21 – 2024-11-13 · Obesity, Overweight
What this study did
Phase 2 (6)
MASH / NASH
NCT05877547 · Merck Sharp & Dohme LLC
2023-06-23 – 2025-12-29 · Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
What this study did
NCT05016882 · Novo Nordisk A/S
2021-08-31 – 2025-03-14 · Non-alcoholic Steatohepatitis
What this study did
NCT04944992 · Merck Sharp & Dohme LLC
2021-08-04 – 2022-10-19 · Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
What this study did
Obesity
NCT07812597 · Beijing QL Biopharmaceutical Co.,Ltd
2026-10-12 – 2028-03-24 · Obesity
What this study did
NCT07073417 · Hangzhou Sciwind Biosciences Co., Ltd.
2025-07-28 – 2027-08-23 · Obesity, Weight Management
What this study did
NCT07836140 · Second Affiliated Hospital of Soochow University
2024-04-22 – 2026-04-30 · Obesity / Overweight
What this study did
Phase 1 (6)
Obesity
NCT07940582 · Novo Nordisk A/S
2026-11-13 – 2028-05-29 · Overweight, Obesity
What this study did
NCT07767175 · Novo Nordisk A/S
2026-08-12 – 2027-09-23 · Overweight, Obesity
What this study did
NCT07673900 · Terrestrial Bio, Inc.
2026-06-15 – 2027-05-18 · Overweight and/or Obesity
What this study did
NCT07430059 · Vivani Medical, Inc
2026-07 – 2027-01 · Obesity & Overweight
What this study did
NCT06745284 · Boehringer Ingelheim
2025-03-26 – 2026-12-01 · Obesity
What this study did
NCT06830343 · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
2025-02-27 – 2026-10-01 · Overweight or Obesity
What this study did
Phase 4 (2)
Obesity
NCT06410352 · University Medical Center, Kazakhstan
2024-03-01 – 2026-07-31 · Metabolic Syndrome
What this study did
Early phase / not applicable (1)
Obesity
NCT06989177 · Chinese Academy of Sciences
2025-06-10 – 2026-12-31 · Obesity, Homeostasis, Weight Loss, Probiotic Intervention
What this study did
Studied as part of a combination product (10)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (4)
Obesity
NCT06780449 · Novo Nordisk A/S
2025-02-10 – 2028-10-31 · Obesity
What this study did
NCT07011667 · Novo Nordisk A/S
2025-06-03 – 2028-10-17 · Obesity
What this study did
NCT06388187 · Novo Nordisk A/S
2024-06-24 – 2026-04-22 · Obesity
What this study did
NCT06131437 · Novo Nordisk A/S
2023-11-27 – 2026-01-09 · Obesity
What this study did
Phase 1 (6)
Obesity
NCT07184086 · Novo Nordisk A/S
2025-09-26 – 2028-02-09 · Obesity
What this study did
NCT06267092 · Novo Nordisk A/S
2024-02-15 – 2025-12-08 · Overweight, Obesity
What this study did
NCT06207877 · Novo Nordisk A/S
2024-02-23 – 2024-11-22 · Obesity
What this study did
NCT06289504 · Novo Nordisk A/S
2024-02-27 – 2024-11-15 · Obesity
What this study did
NCT04940078 · Novo Nordisk A/S
2021-07-07 – 2022-02-16 · Obesity & Overweight
What this study did
Appears in other studies (8)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (5)
MASH / NASH
NCT07466017 · Cascade Pharmaceuticals, Inc
2026-04-02 – 2027-07-30 · Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
What this study did
Obesity
NCT07446998 · Veru Inc.
2026-03-26 – 2027-12 · Obesity & Overweight, Mobility Disability, HOMA-IR
What this study did
NCT06577090 · Skye Bioscience, Inc.
2024-08-22 – 2027-02-28 · Obesity
What this study did
NCT06282458 · Veru Inc.
2024-04-29 – 2025-08-22 · Muscle Loss, Obesity
What this study did
NCT06500429 · Neurogastrx, Inc.
2024-06-24 – 2024-09-13 · Overweight and Obesity, Healthy
What this study did
Early phase / not applicable (3)
Obesity
NCT07091500 · Washington University School of Medicine
2025-08-11 – 2029-08-01 · Obesity, Skeletal Muscle, Brain Connectivity
What this study did
NCT06836284 · Karolinska Institutet
2026-02-13 – 2027-05-01 · Childhood Obesity, Treatment Adherence
What this study did
NCT07849348 · Peking University People's Hospital
2026-09 – 2027-02 · Obesity; Chronic Kidney Disease; Albuminuria
What this study did

Competitive landscape

This mechanism is crowded: 50 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Obesity: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Semaglutide (Wegovy): this drugApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
NCT03548935: Change in Body Weight (%) (Baseline (week 0) to week 68): Semaglutide 2.4 mg — In-trial observation period: -15.6% (Standard Deviation 10.1); On-treatment observation period: -16.9% (Standard Deviation 9.4) vs Placebo — In-trial observation period: -2.8% (Standard Deviation 6.5); On-treatment observation period: -3.1% (Standard Deviation 6.4)
Liraglutide (Saxenda)ApprovedPeptideGLP-1 receptorReliable signal
NCT02918279: Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54)
NCT01557166: Change From Baseline in Apnoea-hypopnoea Index (AHI) (Week 0, Week 32): Liraglutide 3.0 mg -12.22 events/hour (Standard Deviation 23.34) vs Placebo -6.08 events/hour (Standard Deviation 25.9)
Lixisenatide (Adlyxin / Lyxumia)
Approved(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Naltrexone / Bupropion (Contrave)ApprovedSmall moleculeOpioid receptor / dopamine (combination), Dopamine/norepinephrine transporternot yet graded
NCT03374956: Change in Total Body Weight (baseline to 12 weeks): Intervention Group -7.7% (IQR -11 to -4.7) vs Control Group -6.5% (IQR -11 to -2.3) phase 3 result · pivotal pending
Orforglipron (Foundayo)ApprovedSmall moleculeGLP-1 receptorPartial signal
NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001)
NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met.
Orlistat (Xenical)ApprovedSmall moleculePancreatic/gastric lipaseWeak signalNo reviewed efficacy summary in this indication
Phentermine / Topiramate (Qsymia)ApprovedSmall moleculeNoradrenergic/anticonvulsant (combination)Reliable signal
NCT00553787: Percent Weight Loss From Baseline to Week 56 (Baseline to 56 weeks): VI-0521 Mid 7.81% (Standard Error 0.365) | VI-0521 Top 9.84% (Standard Error 0.275) vs Placebo 1.24% (Standard Error 0.277)
NCT00554216: Percent Weight Loss From Baseline to Week 56 (baseline to 56 weeks): VI-0521 Low 5.1% (Standard Error 0.538) | VI-0521 Top 10.92% (Standard Error 0.392) vs Placebo 1.55% (Standard Error 0.395)
Semaglutide (Wegovy Tablets)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Setmelanotide (Imcivree)ApprovedPeptideMC4RWeak signal
NCT05774756: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984)
NCT03287960: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) (Week 52): Setmelanotide (Entire Study) 45.5% (95% CI 19.96 to 72.88)
Tirzepatide (Zepbound)ApprovedPeptideGLP-1/GIP receptor (dual)Reliable signal
NCT05412004: Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52): Tirzepatide MTD_GPI1 -25.25 events per hour (Standard Error 2.06) | Placebo_GPI1 -5.25 events per hour (Standard Error 2.11) | Tirzepatide MTD_GPI2 -29.27 events per hour (Standard Error 1.99) | Placebo_GPI2 -5.51 events per hour (Standard Error 2.21)
NCT04660643: Percent Change From Randomization in Body Weight at Week 88 (Randomization (Week 36), Week 88): Tirzepatide MTD -6.7 percent change (Standard Error 0.52) vs Placebo 14.8 percent change (Standard Error 0.53)
Albenatide
Phase 3(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorPartial signal
NCT06703021: Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001)
ASC30Phase 3Small moleculeGLP-1 receptorPartial signal
NCT07002905: Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06712836: Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results).
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)Partial signal
NCT06973681: Placebo-adjusted LS-mean body weight reductions of 10.77% to 19.78% across BGM0504 dose groups (120 Chinese adults with obesity)
BofanglutidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT03856047: Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2)
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT05813925: Change in body weight at week 68: -18.4% (SE 0.7) CagriSema vs -11.9% (SE 0.7) semaglutide alone; ETD -6.5 percentage points (95% CI -8.4 to -4.6; p<0.0001)
DA-302168SPhase 3Small moleculeGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
EcnoglutidePhase 3PeptideGLP-1 receptorReliable signal
NCT05813795: Co-primary 1, percent change in body weight from baseline to week 40 (treatment-policy estimand): ecnoglutide 1.2 mg -9.1%, 1.8 mg -10.9%, 2.4 mg -13.2% vs placebo +0.1%; treatment differences -9.2% (97% CI -11.0 to -7.5), -11.1% (-13.1 to -9.1) and -13.3% (-15.3 to -11.3); all p<0.0001, met. Co-primary 2, weight reduction of at least 5% at week 40: 77%, 84% and 87% vs 16%; differences 60% (98% CI 50 to 71), 68% (58 to 78) and 70% (61 to 80); all p<0.0001, met.
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT05997576: Body weight vs placebo in overweight or obese adults (pivotal Phase 3): CSPC states the product significantly reduced body weight compared with placebo; no figures released. The announcement does not report the co-primary proportion with at least 5% weight loss (CSPC announcement, 13 October 2025).
EfpeglenatidePhase 3PeptideGLP-1 receptorReliable signal
NCT06174779: Percent change in body weight from baseline at Week 40: -9.75% (efpeglenatide/HM11260C) vs -0.95% (placebo); least-squares mean difference -8.13 percentage points, statistically significant
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signalNo reviewed efficacy summary in this indication
EloralintidePhase 3PeptideAmylin receptorReliable signal
NCT06230523: Body weight, percent change from baseline at Week 48: eloralintide 1 mg -9.4%, 3 mg -12.4%, 6 mg -17.6%, 9 mg -20.1%, 6/9 mg -19.9% and 3/6/9 mg -16.5% vs placebo -0.4%.
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)Reliable signal
NCT06525935: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001)
Exendin-4 Fc Fusion (JY09)
Phase 3(overall)
Protein / enzyme therapeuticGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
HDG1901
Phase 3(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HDM1005Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
IcoSema (Kyinsu)
Phase 3(overall)
PeptideInsulin receptor (basal), GLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
LenbelintidePhase 3PeptideAmylin receptorPartial signalNo reviewed efficacy summary in this indication
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistReliable signal
NCT05669599: Primary endpoint percent change in body weight baseline to week 52 (treatment policy estimand): -12.3% to -16.2% across doses vs -2.5% placebo (obesity cohort); -8.4% to -12.3% vs -1.7% placebo (obesity-diabetes cohort)
MazdutidePhase 3PeptideGLP-1/glucagon receptor (dual)Reliable signal
NCT05607680: Co-primary 1, percent change in body weight from baseline to week 32 (treatment-policy estimand): mazdutide 4 mg -10.09% (95% CI -11.15 to -9.04), 6 mg -12.55% (95% CI -13.64 to -11.45) vs placebo +0.45% (95% CI -0.61 to 1.52); P<0.001 for both doses vs placebo, met. Co-primary 2, weight reduction of at least 5% at week 32: 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% (placebo); P<0.001 for both doses vs placebo, met.
MDR-001Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
MibavademabPhase 3Monoclonal antibodyLeptin receptorPartial signalNo reviewed efficacy summary in this indication
Noiiglutide
Phase 3(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
OlatorepatidePhase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06839664: Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo.
Pegloxenatide (Fulaimei)
Phase 3(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
PetrelintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Partial signal
NCT06662539: Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05).
RAY1225Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)Partial signal
NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract.
NCT05931367: Co-primary 1, WOMAC pain subscale change to week 68 (treatment-regimen estimand): retatrutide 9 mg -4.0 points (-67.2%), 12 mg -3.7 points (-62.6%) vs placebo -2.1 points (-35.1%); statistically significant for each dose per the sponsor (p not printed), met. Co-primary 2, percent change in body weight to week 68: 9 mg -20.0%, 12 mg -23.7% vs placebo -4.6%; statistically significant for each dose per the sponsor (p not printed), met.
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06396429: Mean weight loss at Week 48 (treatment policy estimand): up to 17.7% with HRS9531 (16.3 percentage points placebo-adjusted); up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptorReliable signal
NCT06904105: Percent body-weight change at week 44, treatment-policy estimand (prespecified primary): -8.0% (120 mg) and -9.8% (180 mg) vs -2.4% placebo, superiority stated as met (no p-value given). Proportion with at least 5% weight loss at week 44 (registry primary): 58.6% (120 mg) and 68.2% (180 mg); placebo rate and significance not reported.
SurvodutidePhase 3PeptideGLP-1/glucagon receptor (dual)Partial signal
NCT06066515: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo).
NCT06066528: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-2, primary analysis, treatment-regimen estimand): -9.8% survodutide 6.0 mg and -8.2% 3.6 mg vs -3.9% placebo; body weight reduction of at least 5%: 64.5% and 57.6% vs 35.1% (P<0.001 for all comparisons with placebo).
TesofensinePhase 3Small moleculeNoradrenaline/dopamine/serotonin reuptakeReliable signal
NCT00394667: After 24 weeks, mean weight loss with diet and placebo was 2.0%, while tesofensine doses produced significantly greater reductions of 4.5%, 9.2% and 10.6% respectively.
UBT251Phase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
VCT220Phase 3Small moleculeGLP-1 receptorPartial signal
NCT06939296: Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18).
NCT07011797: Phase 2 trial, explicitly named as NCT07011797: primary endpoints met, up to 11.5% weight loss at 36 weeks with CX11 (oral GLP-1 receptor agonist), ongoing weight loss without plateau; gastrointestinal AEs the most common safety finding.
Visepegenatide (PB-119)
Phase 3(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
VK2735Phase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06828055: Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001
ZenagamtidePhase 3PeptideGLP-1/amylin receptor (dual)Weak signal
NCT06064006: Primary outcome, safety (number of treatment-emergent adverse events; no formal efficacy test). Secondary endpoint, estimated mean bodyweight change vs placebo: -24.3% vs -1.1% at week 36 (60 mg), -22.0% vs 1.9% (20 mg, week 36), -16.2% vs 2.3% (5 mg, week 28), -9.7% vs 2.0% (1.25 mg, week 20); p<0.0001 (Parts A-D), p=0.0003 (Part E) (Lancet 2025).
ZovaglutidePhase 3PeptideGLP-1 receptorReliable signal
NCT07020884: Percentage change in body weight from baseline at 24 weeks: -10.6% (80mg monthly), -13.8% (160mg monthly), -12.5% (80mg biweekly), -14.4% (160mg biweekly) vs -2.4% (placebo); p<0.0001.
Efsubaglutide AlfaPhase 2/3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06732960: Efsubaglutide Alfa produced a mean weight reduction of 7.16% (95% CI: -8.08 to -6.24) versus 0.86% with placebo. Overall, 82.5% of Efsubaglutide-treated participants achieved >=5% weight loss (vs. 0% placebo).
ABBV-295Phase 2PeptideAmylin receptorWeak signalFeatured results are safety only in this race
Apitegromab (Isembyld)Phase 2Monoclonal antibodyMyostatin (pro/latent form)Partial signal
NCT06445075: Change from baseline in total Lean Body Mass at 24 weeks: -1.6 kg (-3.4 lbs) with apitegromab+tirzepatide vs -3.5 kg (-7.6 lbs) with placebo+tirzepatide; difference 1.9 kg (4.2 lbs) less lean-mass loss with apitegromab, i.e. 54.9% relative preservation (p=0.001).
ARD-101Phase 2Small moleculeBitter taste receptor (gut)Partial signal
NCT05121441: General-obesity Phase 2 (n=20): ARD-101 produced a 2.51-fold greater reduction in hunger rating (Control of Eating Questionnaire) vs placebo; p=0.015
AT-7687Phase 2PeptideGIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
AZD9550Phase 2PeptideGLP-1/glucagon receptor (dual)Partial signalNo reviewed efficacy summary in this indication
BGM1812Phase 2PeptideAmylin/calcitonin receptor (dual)Weak signal
NCT07224399: Placebo-adjusted weight loss 0.2% to 9.2% (LS mean) across dose groups (0.3 to 7.2 mg once weekly for 1 to 4 weeks); no serious adverse events (sponsor-reported, 7 August 2026)
BI 3034701Phase 2PeptideGLP-1/GIP/NPY2 receptor (triple)Weak signalNo reviewed efficacy summary in this indication
BimagrumabPhase 2Monoclonal antibodyActivin/myostatin type II receptorPartial signal
NCT05616013: Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): 30 mg/kg Bimagrumab -9.25 kilogram (kg) (Standard Error 1.33) | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide -12.73 kilogram (kg) (Standard Error 1.29) | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide -14.31 kilogram (kg) (Standard Error 1.34) | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide -13.86 kilogram (kg) (Standard Error 1.29) | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide -17.79 kilogram (kg) (Standard Error 1.29) vs Placebo + 1.0 mg Semaglutide -9.76 kilogram (kg) (Standard Error 1.25) | Placebo + 2.4 mg Semaglutide -14.24 kilogram (kg) (Standard Error 1.17)
Bremelanotide (Vyleesi)Phase 2PeptideMC4RReliable signal
NCT06565611: BMT-801 study (NCT06565611): weight reduction 4.4% (bremelanotide + tirzepatide) vs 1.6% (placebo); p<0.0001.
DapiglutidePhase 2PeptideGLP-1/GLP-2 receptor (dual)Partial signal
NCT05788601: NCT05788601, primary endpoint (% change in body weight, baseline to week 12): 6 mg dapiglutide vs placebo, difference −2.1%; p=0.076. missed
ECC4703Phase 2—Thyroid hormone receptor beta (THRβ)not yet gradedNo reviewed efficacy summary in this indication
Ecnoglutide (VRB-101)Phase 2PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
EnobosarmPhase 2Small moleculeAndrogen receptor (selective)Partial signal
NCT06282458: Change in total lean body mass at 16 weeks (day 112), enobosarm+semaglutide vs placebo+semaglutide: 71% relative reduction in lean mass loss (p=0.002); 27% greater fat loss vs control
ERX1000Phase 2Small moleculeLeptinWeak signalNo reviewed efficacy summary in this indication
Exenatide (PT320)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Garetosmab (Pasatru)Phase 2Monoclonal antibodyActivin Anot yet gradedNo reviewed efficacy summary in this indication
HM15275Phase 2PeptideGLP-1/GIP/glucagon receptor (triple)Weak signalFeatured results are safety only in this race
HRS-4729Phase 2PeptideGLP-1/GIP/glucagon receptor (triple)Weak signalFeatured results are safety only in this race
LAE102Phase 2Monoclonal antibodyActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
MacupatidePhase 2PeptideGIP receptornot yet gradedNo reviewed efficacy summary in this indication
Metreleptin (Myalept)Phase 2Protein / enzyme therapeuticLeptinPartial signalNo reviewed efficacy summary in this indication
NA-931Phase 2PeptideGLP-1/GIP/glucagon/IGF-1 receptors (quadruple)Partial signal
NCT06564753: Mean body weight reduction from baseline at Week 13: up to 13.8% at the 150 mg daily dose; 11.9% relative to placebo
NimacimabPhase 2Monoclonal antibodyCB1 receptornot yet gradedNo reviewed efficacy summary in this indication
NNC0519-0130Phase 2PeptideGLP-1/GIP receptor (dual)Partial signalNo reviewed efficacy summary in this indication
NNC0662-0419Phase 2PeptideGLP-1 / GIP / Amylin receptorsWeak signalNo reviewed efficacy summary in this indication
Orlistat / Acarbose (EMP16)Phase 2Small moleculeGI lipase + intestinal alpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
ParunoflastPhase 2Small moleculeNLRP3 inflammasome, NLRP3Weak signalFeatured results are safety only in this race
PG-102Phase 2Protein / enzyme therapeuticGLP-1/GLP-2 receptor (dual)Partial signalFeatured results are safety only in this race
Regor GLP-1Phase 2Small moleculeGLP-1 receptorPartial signal
NCT06277934: Safety (this trial's registered primary endpoint): AE-related discontinuation 4%, identical in drug and placebo arms; no treatment-related severe/serious AEs; nausea in 40% and vomiting in 24% of the RGT-075 arm; 1 patient (2%) required dose reduction.
RuvonoflastPhase 2Small moleculeNLRP3 inflammasomePartial signal
NCT07055516: Primary endpoint met: change from baseline in hsCRP up to week 24; effect sizes not yet given (RESOLVE-1, 2026-09-09).
NCT06129409: Phase Ib/IIa trial in 67 obese subjects with elevated CV risk/CRP, 28-day in-clinic dosing. >75% of NT-0796-dosed subjects reached hsCRP ≤2mg/L at day 28 vs <25% of placebo subjects; primary endpoint (hsCRP reduction) met with high statistical significance.
SAL0150
Phase 2(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Taldefgrobep AlfaPhase 2Antibody-derived scaffoldActivin/myostatin type II receptornot yet gradedNo reviewed efficacy summary in this indication
TE-8105Phase 2PeptideGLP-1 receptorWeak signal
NCT06471530: Safety/tolerability (primary): <20% of participants had mild-to-moderate GI symptoms, no severe adverse events. Weight loss: 5 of the B2 cohort participants achieved >5% body weight reduction.
THDBH120Phase 2PeptideGLP-1/GIP receptor (dual)Weak signalFeatured results are safety only in this race
TifeglipronPhase 2Small moleculeGLP-1 receptorPartial signalFeatured results are safety only in this race
TisolagilinePhase 2Small moleculeMAO-Bnot yet gradedNo reviewed efficacy summary in this indication
TrevogrumabPhase 2Monoclonal antibodyMyostatin (GDF8)not yet gradedNo reviewed efficacy summary in this indication
TTP273
Phase 2(overall)
Small moleculeGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
UtreglutidePhase 2PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
ZabopegdutidePhase 2PeptideGLP-1/glucagon receptor (dual)Partial signalFeatured results are safety only in this race
ZT006Phase 2PeptideGLP-1 receptorWeak signalNo reviewed efficacy summary in this indication
ARO-ALK7Phase 1/2RNA / oligonucleotideALK7 (Activin receptor-like kinase 7)not yet gradedNo reviewed efficacy summary in this indication
ARO-INHBEPhase 1/2RNA / oligonucleotideINHBE (Inhibin beta E chain / Activin E)not yet gradedNo reviewed efficacy summary in this indication
GUB-UCN2Phase 1/2PeptideCorticotropin-releasing factor receptor 2not yet gradedNo reviewed efficacy summary in this indication
MET-233iPhase 1/2PeptideAmylin receptorWeak signalNo reviewed efficacy summary in this indication
PB-718Phase 1/2PeptideGLP-1/glucagon receptor (dual)Weak signalNo reviewed efficacy summary in this indication
BMF-650Phase 1Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
DehydraTECH-CBD / SemaglutidePhase 1CombinationOral peptide delivery platform, GLP-1 receptorWeak signalFeatured results are safety only in this race
EfocipegtrutidePhase 1PeptideGLP-1/GIP/glucagon receptor (triple)Weak signalFeatured results are safety only in this race
IBI3032Phase 1Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Liraglutide (HUC2-676)Phase 1PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PF-08642534Phase 1UndisclosedGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PF-08656795Phase 1UndisclosedGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (DWRX5003)Phase 1PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
XW014
Phase 1(overall)
Small moleculeGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication

Large race: only the 106 furthest-along competitors are listed; 24 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(73 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Semaglutide (Wegovy) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
December 2026 (6)
Phase 4MASH / NASHActive not recruiting
Est. primary completion 2026-12 · NCT05195944 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2026-12-31 · NCT05173714 · CT.gov ↗
What to watch
Phase 4ObesityEnrolling by invitation
Est. primary completion 2026-12-31 · NCT07057310 · CT.gov ↗
What to watch
Early phase / not applicableObesityNot yet recruiting
Est. primary completion 2026-12-31 · NCT06825793 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2026-12-31 · NCT06989203 · CT.gov ↗
What to watch
Early phase / not applicableObesityNot yet recruiting
Est. primary completion 2026-12-31 · NCT06546384 · CT.gov ↗
What to watch
2027 (22)
January 2027 (2)
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-01 · NCT04174755 · CT.gov ↗
What to watch
Phase 1ObesityActive not recruiting
Est. primary completion 2027-01-06 · NCT05202353 · CT.gov ↗
What to watch
February 2027 (3)
Phase 2Trichotillomania (Hair-Pulling Disorder), Trichotillomania, Hair Pulling Disorder, Hair Pulling, Hair-Pulling DisorderNot yet recruiting
Est. primary completion 2027-02 · NCT07282769 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2027-02 · NCT07242534 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2027-02-28 · NCT07840729 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2ObesityRecruiting
Est. primary completion 2027-03 · NCT07101939 · CT.gov ↗
What to watch
April 2027 (2)
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-04-02 · NCT07293325 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-04-28 · NCT06854614 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2ObesityNot yet recruiting
Est. primary completion 2027-06 · NCT07411378 · CT.gov ↗
What to watch
Phase 2ObesityActive not recruiting
Est. primary completion 2027-06-14 · NCT07639021 · CT.gov ↗
What to watch
July 2027 (2)
Phase 4ObesityActive not recruiting
Est. primary completion 2027-07-01 · NCT06803888 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-07-31 · NCT06754163 · CT.gov ↗
What to watch
September 2027 (4)
Phase 4ObesityRecruiting
Est. primary completion 2027-09 · NCT07136714 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2027-09-01 · NCT06575738 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2027-09-11 · NCT07845578 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-09-30 · NCT06497595 · CT.gov ↗
What to watch
December 2027 (6)
Phase 3ObesityRecruiting
Est. primary completion 2027-12 · NCT06499857 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-12 · NCT06814938 · CT.gov ↗
What to watch
Phase 1/2ObesityRecruiting
Est. primary completion 2027-12-28 · NCT05746039 · CT.gov ↗
What to watch
Phase 2/3ObesityRecruiting
Est. primary completion 2027-12-30 · NCT06423599 · CT.gov ↗
What to watch
Phase 4ObesityNot yet recruiting
Est. primary completion 2027-12-30 · NCT07783854 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2027-12-31 · NCT06852391 · CT.gov ↗
What to watch
2028 (24)
January 2028 (2)
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-01-23 · NCT07779343 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2028-01-31 · NCT06801015 · CT.gov ↗
What to watch
February 2028 (3)
Early phase / not applicableObesityNot yet recruiting
Est. primary completion 2028-02 · NCT07621640 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-02-01 · NCT07213466 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-02-29 · NCT07732426 · CT.gov ↗
What to watch
April 2028 (2)
Phase 4ObesityNot yet recruiting
Est. primary completion 2028-04 · NCT07859176 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2028-04-28 · NCT07527195 · CT.gov ↗
What to watch
May 2028 (4)
Phase 1Prostate CancerNot yet recruiting
Est. primary completion 2028-05 · NCT07727473 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-05-01 · NCT07633639 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2028-05-03 · NCT07010432 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2028-05-25 · NCT06173778 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3ObesityNot yet recruiting
Est. primary completion 2028-06 · NCT06909006 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2MASH / NASHRecruiting
Est. primary completion 2028-08-31 · NCT03884075 · CT.gov ↗
What to watch
September 2028 (4)
Phase 3ObesityRecruiting
Est. primary completion 2028-09 · NCT07294950 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-09-01 · NCT07770152 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2028-09-06 · NCT07855133 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-09-30 · NCT07589322 · CT.gov ↗
What to watch
October 2028 (1)
Phase 4ObesityNot yet recruiting
Est. primary completion 2028-10 · NCT07859189 · CT.gov ↗
What to watch
November 2028 (2)
Phase 4ObesityNot yet recruiting
Est. primary completion 2028-11 · NCT07859137 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2028-11-15 · NCT06571383 · CT.gov ↗
What to watch
December 2028 (4)
Phase 4ObesityRecruiting
Est. primary completion 2028-12 · NCT07870538 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-12-01 · NCT07592546 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-12-30 · NCT07275697 · CT.gov ↗
What to watch
Phase 2ObesityNot yet recruiting
Est. primary completion 2028-12-31 · NCT07820358 · CT.gov ↗
What to watch
2029 (10)
January 2029 (1)
Phase 4ObesityNot yet recruiting
Est. primary completion 2029-01-01 · NCT07858331 · CT.gov ↗
What to watch
February 2029 (1)
Phase 2Endometrial Cancer, Atypical Hyperplasia, Fertility PerservationRecruiting
Est. primary completion 2029-02 · NCT06073184 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2ObesityNot yet recruiting
Est. primary completion 2029-03 · NCT07909889 · CT.gov ↗
What to watch
April 2029 (3)
Phase 4ObesityNot yet recruiting
Est. primary completion 2029-04 · NCT07859150 · CT.gov ↗
What to watch
Phase 4ObesityNot yet recruiting
Est. primary completion 2029-04 · NCT07859163 · CT.gov ↗
What to watch
Phase 3MASH / NASHActive not recruiting
Est. primary completion 2029-04-25 · NCT04822181 · CT.gov ↗
What to watch
June 2029 (2)
Phase 2ObesityNot yet recruiting
Est. primary completion 2029-06 · NCT07946796 · CT.gov ↗
What to watch
Phase 2/3Kidney Transplant RecipientNot yet recruiting
Est. primary completion 2029-06-30 · NCT06913023 · CT.gov ↗
What to watch
August 2029 (1)
Early phase / not applicableObesityRecruiting
Est. primary completion 2029-08-30 · NCT06885736 · CT.gov ↗
What to watch
December 2029 (1)
Phase 4ObesityRecruiting
Est. primary completion 2029-12-31 · NCT07900074 · CT.gov ↗
What to watch
2030 (5)
March 2030 (1)
Phase 3ObesityRecruiting
Est. primary completion 2030-03-20 · NCT07253285 · CT.gov ↗
What to watch
May 2030 (1)
Phase 4ObesityRecruiting
Est. primary completion 2030-05-31 · NCT07872904 · CT.gov ↗
What to watch
September 2030 (2)
Phase 2/3Gestational Diabetes Mellitus (GDM), Metabolic SyndromeNot yet recruiting
Est. primary completion 2030-09-01 · NCT07797036 · CT.gov ↗
What to watch
Phase 3Aortic Stenosis, Heart FailureNot yet recruiting
Est. primary completion 2030-09-01 · NCT07090343 · CT.gov ↗
What to watch
November 2030 (1)
Phase 3ObesityRecruiting
Est. primary completion 2030-11-01 · NCT06934655 · CT.gov ↗
What to watch
2031 (5)
January 2031 (2)
Phase 2ObesityNot yet recruiting
Est. primary completion 2031-01-01 · NCT07731256 · CT.gov ↗
What to watch
Phase 4ObesityNot yet recruiting
Est. primary completion 2031-01-31 · NCT06977438 · CT.gov ↗
What to watch
March 2031 (1)
Phase 3ObesityNot yet recruiting
Est. primary completion 2031-03 · NCT07845994 · CT.gov ↗
What to watch
April 2031 (1)
Phase 3ObesityNot yet recruiting
Est. primary completion 2031-04-30 · NCT07021937 · CT.gov ↗
What to watch
July 2031 (1)
Phase 4ObesityNot yet recruiting
Est. primary completion 2031-07-30 · NCT07769047 · CT.gov ↗
What to watch
2032 (1)
April 2032 (1)
Phase 3ObesityNot yet recruiting
Est. primary completion 2032-04-30 · NCT07949474 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(12)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

7 September 2026Topline resultSTEP Young Phase 3 meets its primary endpoint
Novo Nordisk · Source ↗
July 2026ApprovalWegovy 7.2 mg single-dose pen approved in the EU
EU, EMA · Source ↗
11 June 2026ApprovalWegovy pill (semaglutide tablets) approved in the UK
UK, MHRA · Source ↗
9 April 2026ApprovalEMA approves Wegovy injection 48-hour controlled-temperature delivery
EU, EMA · Source ↗
19 March 2026ApprovalFDA approves the Wegovy 7.2 mg weekly dose (Wegovy HD)
US, FDA · Source ↗
17 February 2026ApprovalEC approves Wegovy 7.2 mg dose for adults with obesity
EU, EMA · Source ↗
22 December 2025ApprovalFDA approves Wegovy pill (oral semaglutide 25 mg) for weight loss
US, FDA · Source ↗
26 November 2025Filing submittedsNDA submitted to FDA for Wegovy 7.2 mg
US, FDA · Source ↗
Q4 2025FDA action dateFDA action date for oral Wegovy set for Q4 2025
US, FDA · Source ↗
15 August 2025ApprovalFDA approves Wegovy for MASH with moderate to advanced liver fibrosis
US, FDA · Source ↗
2 May 2025Filing acceptedFDA accepts NDA for oral Wegovy (semaglutide) 25 mg
US, FDA · Source ↗
19 November 2024Topline resultESSENCE part 1 results for semaglutide 2.4 mg in MASH